Patients with coronary heart disease and chronic kidney disease - the possibility of applying cell adhesion molecule as a predictor of disease progression-Reference-Cited by-同舟云学术

Patients with coronary heart disease and chronic kidney disease - the possibility of applying cell adhesion molecule as a predictor of disease progression

Published:2023-06-21 Issue:2 Volume:4 Page:56-63
ISSN:2712-8156
Container-title:South Russian Journal of Therapeutic Practice
language:
Short-container-title:jour

Author:

Samakaev A. S.¹^ORCID,Glova S. E.¹^ORCID,Zimoveyskaya E. E.¹^ORCID,Khaisheva L. A.¹^ORCID,Shlyk S. V.¹^ORCID

Affiliation:

1. Rostov State Medical University

Abstract

Objective: to study the level of type 1 vascular endothelial adhesion molecule in patients with coronary heart disease depending on the stage of chronic kidney disease. Material and methods: the study included 115 patients, mean age was 67.56±12.42 years (63 men, 52 women) with ischemic heart disease (CAD), stable angina (tension), functional class 1–3, chronic kidney disease (CKD) C1–C3. The level of the vascular endothelial adhesion molecule type 1 (VCAM 1) was assessed using the enzyme immunoassay kit for the quantitative determination of human VCAM 1 ThermoFisher scientific. Results: in patients with CAD and CKD, the level of serum VCAM 1 progressively increases as angina pectoris worsens and can be regarded as an early marker of CAD progression. The level of VCAM 1 does not depend on the stage of CKD. When studying the correlation relationships between the level of serum VCAM 1 and clinical and laboratory data, it was found that there is a correlation relationship between VCAM 1 and the level of SBP and DBP. Conclusion: in patients with CAD and CKD, it is advisable to use the determination of the level of VCAM 1 to identify patients with a high risk of cardiovascular complications.

Publisher

Rostov State Medical University

Subject

General Medicine

Reference16 articles.

1. Резник Е.В., Никитин И.Г. Кардиоренальный синдром у больных с сердечной недостаточностью как этап кардиоренального континуума (часть i): определение, классификация, патогенез, диагностика, эпидемиология (обзор литературы). Архивъ внутренней медицины. 2019; 9(1):5-22. DOI: 10.20514/2226-6704-2019-9-1-5-22

2. Kamińska J, Stopiński M, Mucha K, Jędrzejczak A, Gołębiowski M, Niewczas MA, et al. IL 6 but not TNF is linked to coronary artery calcification in patients with chronic kidney disease. Cytokine. 2019;120:9-14. doi: 10.1016/j.cyto.2019.04.002

3. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. doi: 10.15829/1560-4071-2020-4076.

4. Арутюнов А.Г., Башкинов Р.А., Батлук Т.И., Мельников Е.С., Ермилова А.Н. Острое повреждение почек у пациентов с хронической сердечной недостаточностью. Южно-Российский журнал терапевтической практики. 2021;2(3):6-17. Doi: 10.21886/2712-8156-2021-2-3-6-17.

5. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12. Erratum in: Ann Intern Med. 2011;155(6):408. PMID: 19414839; PMCID: PMC2763564. doi: 10.7326/0003-4819-150-9-200905050-00006.